Analyst Samantha Semenkow from Citi maintained a Buy rating on Biohaven Ltd. and decreased the price target to $14.00 from $28.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Samantha Semenkow has given her Buy rating due to a combination of factors surrounding Biohaven Ltd.’s strategic focus and financial positioning. The company is shifting its attention to a prioritized pipeline, particularly the upcoming Phase 3 data for opakalim (BHV-7000) in focal epilepsy, which is expected in the first half of 2026. Additionally, there are promising developments in other areas such as Graves’ disease and IgA nephropathy, which could drive future growth.
Furthermore, Biohaven’s recent $175 million offering has alleviated immediate financial concerns, providing a buffer to support the company until potential value-driving results are achieved. While there is cautious optimism regarding the high-risk, high-reward nature of the major depressive disorder data expected by the end of 2025, the overall setup presents a favorable opportunity for investors. The revised target price of $14 per share reflects these strategic adjustments and financial considerations.
In another report released on November 10, TD Cowen also maintained a Buy rating on the stock with a $15.00 price target.